Comments on: A Genetic Variation Makes Plavix Less Effective http://www.pharmalot.com/2008/12/a-genetic-variation-makes-plavix-less-effective/ News, Comment and Conversation Fri, 10 Feb 2012 20:58:22 +0000 http://wordpress.org/?v=2.6.2 By: Agency Employee http://www.pharmalot.com/2008/12/a-genetic-variation-makes-plavix-less-effective/#comment-385439 Agency Employee Tue, 23 Dec 2008 15:06:18 +0000 http://www.pharmalot.com/?p=18877#comment-385439 Talk about timing. Here's my post from yesterday on another thread. December 22nd, 2008 2:03 pm http://www.pharmalot.com/2008/12/pdl-moves-headquarters-near-the-ceos-home/#comment-385408 “This past week the press indicated that approvals will likely get easier in the next year or two. (Guess why.) Plus Von Eschenbach and FDA management have indicated in the past that things will get better for companies under the critical path initiative by 2010, and we will see the fruit of personalized medicine by 2015. These last statements were accompanied by statements that co-marketing of drug and devices for personalized medicine will save drugs from being removed from the market as well as extend patent protections. (statements made June 2007)” It's not only efficacy, but knowledge about unsafe drugs that this will save. The companies and FDA are currently intentionally putting unsafe drugs on the market. Then when Woodcock's safety first initiative finds (already known) toxicities after approval genetic tests will be used to keep the drug on the market but in a restricted population. The genetic testing will be a windfall ($) for the companies but in the interim they will have sold to many more people and the genetic tests will also diminish fear and keep sales up as well as then extend patent protections. Plus with preemption no one can be held responsible for truly horrific and widespread toxicities. Talk about timing.

Here’s my post from yesterday on another thread.

December 22nd, 2008 2:03 pm

http://www.pharmalot.com/2008/12/pdl-moves-headquarters-near-the-ceos-home/#comment-385408

“This past week the press indicated that approvals will likely get easier in the next year or two. (Guess why.) Plus Von Eschenbach and FDA management have indicated in the past that things will get better for companies under the critical path initiative by 2010, and we will see the fruit of personalized medicine by 2015. These last statements were accompanied by statements that co-marketing of drug and devices for personalized medicine will save drugs from being removed from the market as well as extend patent protections. (statements made June 2007)”

It’s not only efficacy, but knowledge about unsafe drugs that this will save. The companies and FDA are currently intentionally putting unsafe drugs on the market. Then when Woodcock’s safety first initiative finds (already known) toxicities after approval genetic tests will be used to keep the drug on the market but in a restricted population.

The genetic testing will be a windfall ($) for the companies but in the interim they will have sold to many more people and the genetic tests will also diminish fear and keep sales up as well as then extend patent protections. Plus with preemption no one can be held responsible for truly horrific and widespread toxicities.

]]>